Tech Company Financing Transactions
Surge Therapeutics Funding Round
Surge Therapeutics, operating out of Cambridge, raised $32 million from Bioluminescence Ventures, 8VC and Alumni Ventures.
Transaction Overview
Company Name
Announced On
7/19/2023
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series B
Investors
Proceeds Purpose
The funding will be used to further the development of the SURGE� intraoperative immunotherapy approach, expand the team, and advance multiple clinical trials for its injectable biodegradable hydrogel, which may be administered during any surgical oncology procedure.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA Undisclosed
USA
Cambridge, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
SURGE works relentlessly to create a world where all cancer patients undergoing surgical tumor resection can receive intraoperative immunotherapy to prevent post-surgical recurrence and metastasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Goldberg
VP - Operations
Kayti Aviano
Browse more venture capital transactions:
Prev: 7/19/2023: Preply venture capital transaction
Next: 7/19/2023: PingSafe venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs